Cargando…

Prasugrel for Secondary Prevention of Thrombotic Stroke

Detalles Bibliográficos
Autor principal:	Yagita, Yoshiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981352/ https://www.ncbi.nlm.nih.gov/pubmed/35908883 http://dx.doi.org/10.5551/jat.ED213

Ejemplares similares

Review of Prasugrel for the Secondary Prevention of Atherothrombosis
por: Spinler, Sarah A., et al.
Publicado: (2009)

Cholesterol and Inflammation in Stroke Recurrence
por: Yagita, Yoshiki
Publicado: (2019)

Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency
por: Lopez, Yanet Parodis, et al.
Publicado: (2016)

Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III)
por: Kitazono, Takanari, et al.
Publicado: (2023)

Prasugrel, a new medicine for preventing blockages in the arteries
por: Wang, Zhi-Mei, et al.
Publicado: (2010)

Stroke Secondary Prevention: Everyone’s Business
por: Lawrence, Maggie, et al.
Publicado: (2022)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Prasugrel in critically ill patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Prasugrel-Induced Hypersensitivity Skin Reaction
por: Kim, Soo-Han, et al.
Publicado: (2014)

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions
por: Kumari, Priti, et al.
Publicado: (2018)

Prasugrel for the treatment of patients with acute coronary syndrome
por: Marzot, Filippo, et al.
Publicado: (2009)

TRITON and Beyond: New Insights into the Profile of Prasugrel
por: Jakubowski, Joseph A, et al.
Publicado: (2012)

Eversion endarterectomy under full prasugrel treatment
por: Kotsis, Thomas, et al.
Publicado: (2017)

Low-Dose Prasugrel in Treatment of Cerebral Aneurysms
por: Kang, Hyun-Seung
Publicado: (2018)

Critical Review of Prasugrel for Formulary Decision Makers
por: Schafer, Jeremy
Publicado: (2009)

The Usefulness of Prasugrel as Rescue Medication in Neuroendovascular Therapy
por: Niimi, Jun, et al.
Publicado: (2020)

Prasugrel, a Platelet P2Y(12) Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia
por: Ohno, Kousaku, et al.
Publicado: (2016)

Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial
por: Kitazono, Takanari, et al.
Publicado: (2021)

Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
por: Jeger, Raban V., et al.
Publicado: (2019)

Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers
por: Ancrenaz, Virginie, et al.
Publicado: (2013)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Complement in Secondary Thrombotic Microangiopathy
por: Palma, Lilian Monteiro Pereira, et al.
Publicado: (2020)

Successful Prasugrel Rescue Therapy in Clopidogrel Resistant Patients Who Had Recurrent Stent Thrombosis of Drug-Eluting-Stent: The Role of Prasugrel in Clopidogrel Nonresponders
por: Lee, Seung-Hyun, et al.
Publicado: (2013)

Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels
por: Parker, William A. E., et al.
Publicado: (2020)

Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
por: Hillegass, William B, et al.
Publicado: (2011)

Stability-indicating HPLC Method for Simultaneous Determination of Aspirin and Prasugrel
por: Patel, Shital M., et al.
Publicado: (2013)

Bleeding events and maintenance dose of prasugrel: BLESS pilot study
por: Carrabba, Nazario, et al.
Publicado: (2016)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
por: Niijima, Satoshi, et al.
Publicado: (2018)

Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada
por: Lordkipanidzé, Marie, et al.
Publicado: (2020)

Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
por: Kitazono, Takanari, et al.
Publicado: (2018)

Pharmacodynamic assessment of prasugrel and clopidogrel in patients with non-cardioembolic stroke: a multicenter, randomized, active-control clinical trial
por: Yamaguchi, Takenori, et al.
Publicado: (2019)

Romanian registry for interventional treatment in acute stroke: a hope for secondary prevention through medication adherence improvement
por: Tiu, Cristina, et al.
Publicado: (2023)

Thrombotic thrombocytopenic purpura secondary to Streptococcus
por: Morrin, M.J., et al.
Publicado: (2006)

Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study
por: Kumar, Arun, et al.
Publicado: (2022)

Toward prevention of stroke
por: Thomas, Sanjeev V.
Publicado: (2010)

Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura
por: Scully, Marie, et al.
Publicado: (2017)

Recognition of thrombotic risk of thrombocytosis in iron deficiency
por: Al-Samkari, Hanny, et al.
Publicado: (2021)

Thrombotic Disorders and Antithrombotic Treatments Special Issue
por: Micco, Pierpaolo Di
Publicado: (2022)

A third form of thrombotic thrombocytopenic purpura?
por: Lämmle, Bernhard
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pnjeekgdmfb5cc5hu94erhviaq